

Drug withdrawal notice for Tazverik (tazemetostat)

To assist you in the care of your patients, Humana is alerting you to the market withdrawal of Tazverik® (tazemetostat) by Ipsen on March 9, 2026.¹ We recommend you review your medical records and contact all patients for whom you have prescribed this medication to warn them about the withdrawal.

Ipsen announced the decision to voluntarily withdraw Tazverik (tazemetostat) in all indications from all of its markets in response to emerging data from the ongoing Phase Ib/III SYMPHONY-1 trial. The Independent Data Monitoring Committee has advised that, because of adverse events of secondary hematologic malignancies, the risks could outweigh any potential benefits for patients within the treatment regimen.

Medications included in this withdrawal

Please visit [Ipsen's website](#) for more details on the market withdrawal.

Information for providers:¹

- We sent a letter to your Humana-covered patients with a claim for Tazverik and asked them to contact their providers if they have experienced problems that may be related to using this prescription drug product. Providers should stop prescribing Tazverik and discuss alternative treatment options with their patients.
- Providers with questions can contact Ipsen Medical Information by phone at 855-463-5127, Monday – Friday, 8 a.m. – 5 p.m., Central time, or by email at medinfo.usa@ipsen.com.
- Patients can report adverse reactions or quality problems experienced with the use of this product to the FDA's MedWatch Adverse Event Reporting Program online, by phone or by fax.
 - **Online:** Submit the [report](#).
 - Select "FDA Form 3500."
 - **Phone or fax:** Download the [form](#).
 - Report by phone at 800-FDA-1088 (332-1088) Monday – Friday, 8 a.m. – 4:30 p.m., Eastern time, or submit by fax to 800-FDA-0178 (332-0178).

Note: A reporting form also can be requested by calling 800-FDA-1088 (332-1088). Complete and return to the address on the pre-addressed form or by fax to 800-FDA-0178 (332-0178).

Reference

1. "Ipsen voluntarily withdraws Tazverik® (tazemetostat) in follicular lymphoma and epithelioid sarcoma," Ipsen, last accessed March 31, 2026, <https://www.ipsen.com/press-release/ipsen-voluntarily-withdraws-tazverik-tazemetostat-in-follicular-lymphoma-and-epithelioid-sarcoma-3251503/>